Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 5/2006

01-05-2006 | Original Article

Costs and quality of life associated with osteoporosis-related fractures in Sweden

Authors: Fredrik Borgström, Niklas Zethraeus, Olof Johnell, Lars Lidgren, Sari Ponzer, Olle Svensson, Peter Abdon, Ewald Ornstein, Karl Lunsjö, Karl Göran Thorngren, Ingemar Sernbo, Clas Rehnberg, Bengt Jönsson

Published in: Osteoporosis International | Issue 5/2006

Login to get access

Abstract

This prospective observational data collection study assessed the cost and quality of life related to hip, vertebral and wrist fracture 1 year after the fracture, based on a patient sample consisting of 635 male and female patients surviving a year after fracture. Data regarding resource use and quality of life related to fractures was collected by questionnaires at baseline, 4 months and 12 months. Information was collected by the use of patients’ records, register sources and by asking the patient. Quality of life was estimated with the EQ-5D questionnaire. Costs were estimated from a societal perspective, including direct and indirect costs. The mean fracture-related cost the year after a hip, vertebral and wrist fracture were estimated, in euros (€), at €14,221, €12,544 and €2,147, respectively [converted from Swedish krona (SEK) at an exchange rate of 9.1268 SEK/€]. The mean reduction in quality of life was estimated at 0.17, 0.26 and 0.06 for hip, vertebral and wrist fracture, respectively. Based on the results, the yearly burden of osteoporosis in Sweden could be estimated at €0.5 billion (SEK 4.6 billion). The patient sample for vertebral fracture was fairly small and included a high proportion of fractures leading to hospitalization, but they indicate a higher cost and loss of quality of life related to vertebral fracture than previously perceived.
Footnotes
1
The participating centers were: Södersjukhuset in Stockholm, Malmö University Hospital, Lund University Hospital, Norrlands University Hospital, The Hospital in Ystad, Helsingborg Hospital and Hässleholm Hospital.
 
2
The following pharmaceutical categories were included: calcium and vitamin D, estrogens, bisphosphonates, glucocorticoids and pain medication.
 
Literature
1.
Osteoporos—prevention, diagnostik och behandling (2003). Stockholm
2.
Lippuner K, Golder M, Greiner R (2005) Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int 16 [Suppl 2]:S8–S17CrossRefPubMed
3.
Wong MK, Arjandas, Ching LK, Lim SL, Lo NN (2002) Osteoporotic hip fractures in Singapore—costs and patients’ outcome. Ann Acad Med Singapore 31:3–7PubMed
4.
Gabriel SE, Tosteson AN, Leibson CL, Crowson CS, Pond GR, Hammond CS, Melton LJ 3rd (2002) Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 13:323–330CrossRefPubMed
5.
Koeck CM, Schwappach DL, Niemann FM, Strassmann TJ, Ebner H, Klaushofer K (2001) Incidence and costs of osteoporosis-associated hip fractures in Austria. Wien Klin Wochenschr 113:371–377PubMed
6.
Wiktorowicz ME, Goeree R, Papaioannou A, Adachi JD, Papadimitropoulos E (2001) Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int 12:271–278CrossRefPubMed
7.
Reginster JY, Gillet P, Ben Sedrine W, Brands G, Ethgen O, de Froidmont C, Gosset C (1999) Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics 15:507–514CrossRefPubMed
8.
Zethraeus N, Gerdtham UG (1998) Estimating the costs of hip fracture and potential savings. Int J Technol Assess Health Care 14:255–267PubMedCrossRef
9.
Dolan P, Torgerson DJ (1998) The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 8:611–617CrossRefPubMed
10.
Zethraeus N, Stromberg L, Jonsson B, Svensson O, Ohlen G (1997) The cost of a hip fracture. Estimates for 1,709 patients in Sweden. Acta Orthop Scand 68:13–17PubMedCrossRef
11.
Chrischilles E, Shireman T, Wallace R (1994) Costs and health effects of osteoporotic fractures. Bone 15:377–386CrossRefPubMed
12.
Nurmi I, Narinen A, Luthje P, Tanninen S (2003) Cost analysis of hip fracture treatment among the elderly for the public health services: a 1-year prospective study in 106 consecutive patients. Arch Orthop Trauma Surg 123:551–554CrossRefPubMed
13.
Holmberg S, Thorngren KG (1988) Consumption of hospital resources for femoral neck fracture. Acta Orthop Scand 59:377–381PubMed
14.
Borgquist L, Lindelow G, Thorngren KG (1991) Costs of hip fracture. Rehabilitation of 180 patients in primary health care. Acta Orthop Scand 62:39–48PubMed
15.
Haentjens P, Autier P, Barette M, Boonen S (2001) The economic cost of hip fractures among elderly women. A one-year, prospective, observational cohort study with matched-pair analysis. Belgian Hip Fracture Study Group. J Bone Joint Surg Am 83A:493–500
16.
De Laet CE, van Hout BA, Burger H, Weel AE, Hofman A, Pols HA (1999) Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos Int 10:66–72PubMedCrossRef
17.
Zethraeus N, Borgström F, Johnell O, Kanis J, Jönsson B(2002) Costs and quality of life associated with osteoporosis related fractures—results from a Swedish Survey. Stockholm School of Economics, Stockholm
18.
19.
20.
Janzon M, Levin LA, Swahn E (2002) Cost-effectiveness of an invasive strategy in unstable coronary artery disease; results from the FRISC II invasive trial. The fast revascularisation during instability in coronary artery disease trial. Eur Heart J 23:31–40CrossRefPubMed
21.
Apoteket (Swedish national pharmacy). Apotekets varuregister. December 2003, Stockholm
22.
23.
24.
25.
Drummond M, O’Brien B, Stoddart G, Torrance G (1997) Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford
26.
Gold M, Siegel J, Russell L (eds) (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York
27.
Vägverket. Vägverkets samhällsekonomiska kalkymodell. Ekonomisk teori och värderingar (1997) Vägverket (Swedish Road Authority), Stockholm
28.
29.
30.
Burstrom K, Johannesson M, Diderichsen F (2001) Swedish population health-related quality of life results using the EQ-5D. Qual Life Res 10:621–635CrossRefPubMed
31.
Wackerly DD, Mendenhall W, Schaeffer RL (1996) Mathematical statistics with applications. Duxbury Press, Belmont
32.
Briggs AH, Wonderling DE, Mooney CZ (1997) Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 6:327–340PubMedCrossRef
33.
Neter J, Kutner MH, Nachtsheim CJ, Wasserman W (1996) Applied linear statistical models. McGraw-Hill, Chicago
34.
Gujarati DN (2003) Basic econometrics. McGraw-Hill, New York
35.
Johnell O, Kanis JA, Jonsson B, Oden A, Johansson H, De Laet C (2005) The burden of hospitalised fractures in Sweden. Osteoporos Int 16:222–228CrossRefPubMed
36.
37.
Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D, Jonsson B (2004) Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. Pharmacoeconomics 22:1153–1165CrossRefPubMed
38.
Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (Fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305–314CrossRefPubMed
39.
Jonsson B, Christiansen C, Johnell O, Hedbrandt J (1995) Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporos Int 5:136–142CrossRefPubMed
40.
Tosteson AN, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ 3rd (2001) Impact of hip and vertebral fractures on quality adjusted life years. Osteoporos Int 12:1042–1049PubMedCrossRef
41.
Gabriel SE, Kneeland TS, Melton LJ 3rd, Moncur MM, Ettinger B, Tosteson AN (1999) Health-related quality of life in economic evaluations for osteoporosis: whose values should we use? Med Decis Making 19:141–148PubMedCrossRef
42.
Salkeld G, Cameron ID, Cumming RG, Easter S, Seymour J, Kurrle SE, Quine S (2000) Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ 320:341–346CrossRefPubMed
43.
Brazier JE, Green C, Kanis JA (2002) A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 13:768–776CrossRefPubMed
44.
Tidermark J, Zethraeus N, Svensson O, Tornkvist H, Ponzer S (2002) Femoral neck fractures in the elderly: functional outcome and quality of life according to EuroQol. Qual Life Res 11:473–481CrossRefPubMed
45.
Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent vertebral fractures. J Bone Miner Res 15:1384–1392PubMedCrossRef
46.
Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108–112PubMedCrossRef
47.
Dolan P, Torgerson D, Kakarlapudi TK (1999) Health-related quality of life of Colles’ fracture patients. Osteoporos Int 9:196–199CrossRefPubMed
48.
Henriksson F, Agardh CD, Berne C, Bolinder J, Lonnqvist F, Stenstrom P, Ostenson CG, Jonsson B (2000) Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 248:387–396CrossRefPubMed
49.
Henriksson F, Fredrikson S, Masterman T, Jonsson B (2001) Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol 8:27–35CrossRefPubMed
50.
Ekman M, Zethraeus N, Dahlström U, Höglund C (2002) Är behandling av hjärtsvikt med betablockerare kostnadseffektiv? Läkartidningen 99
51.
Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B (2004) Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7:518–528CrossRefPubMed
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
Metadata
Title
Costs and quality of life associated with osteoporosis-related fractures in Sweden
Authors
Fredrik Borgström
Niklas Zethraeus
Olof Johnell
Lars Lidgren
Sari Ponzer
Olle Svensson
Peter Abdon
Ewald Ornstein
Karl Lunsjö
Karl Göran Thorngren
Ingemar Sernbo
Clas Rehnberg
Bengt Jönsson
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 5/2006
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-005-0015-8

Other articles of this Issue 5/2006

Osteoporosis International 5/2006 Go to the issue

Original Article

Computer-aided system for measuring the mandibular cortical width on dental panoramic radiographs in identifying postmenopausal women with low bone mineral density

Original Article

Maintenance of muscle strength may counteract weight-loss-related postmenopausal bone loss—a population-based approach

Original Article

Serum osteoprotegerin and receptor activator of nuclear factor-κB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?

Original Article

Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial

Original Article

Community-dwelling seniors who present to the emergency department with a fall do not receive Guideline care and their fall risk profile worsens significantly: a 6-month prospective study

Original Article

Influence of duration of total breast-feeding on bone mineral density in a Turkish population: does the priority of risk factors differ from society to society?